AMEX:MTNB

Stock Analysis Report

Executive Summary

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Matinas BioPharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MTNB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-25.5%

MTNB

2.5%

US Biotechs

-2.0%

US Market


1 Year Return

-50.8%

MTNB

-0.9%

US Biotechs

-15.1%

US Market

Return vs Industry: MTNB underperformed the US Biotechs industry which returned 1.6% over the past year.

Return vs Market: MTNB underperformed the US Market which returned -10.7% over the past year.


Shareholder returns

MTNBIndustryMarket
7 Day-25.5%2.5%-2.0%
30 Day-50.8%-8.3%-19.7%
90 Day-75.8%-4.1%-23.2%
1 Year-50.8%-50.8%-0.2%-0.9%-13.4%-15.1%
3 Year-81.2%-81.2%13.8%10.9%10.9%3.7%
5 Year-54.9%-54.9%-7.2%-11.6%28.4%14.4%

Price Volatility Vs. Market

How volatile is Matinas BioPharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?

3.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MTNB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MTNB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MTNB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MTNB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTNB is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTNB's revenue (70.4% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: MTNB's revenue (70.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Matinas BioPharma Holdings performed over the past 5 years?

-11.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MTNB is currently unprofitable.

Growing Profit Margin: MTNB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MTNB is unprofitable, and losses have increased over the past 5 years at a rate of -11% per year.

Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: MTNB has a negative Return on Equity (-52.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Matinas BioPharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MTNB's short term assets ($29.9M) exceed its short term liabilities ($3.1M).

Long Term Liabilities: MTNB's short term assets ($29.9M) exceed its long term liabilities ($4.1M).


Debt to Equity History and Analysis

Debt Level: MTNB is debt free.

Reducing Debt: MTNB currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: MTNB has a low level of unsold assets or inventory.

Debt Coverage by Assets: MTNB's debt is not covered by short term assets (assets are -3.3690140782865E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTNB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MTNB has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -13.4% each year.


Next Steps

Dividend

What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Jerry Jabbour (45yo)

2.08s

Tenure

US$1,325,176

Compensation

Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M ...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD605.16K).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jerome Jabbour
Co-Founder2.08yrsUS$1.33m0.41% $428.9k
Keith Kucinski
Chief Financial Officer1.25yrsUS$774.05k0.048% $50.7k
Theresa Matkovits
Chief Development Officer1.5yrsUS$698.14kno data
James Ferguson
Chief Medical Officer1.17yrsUS$781.38kno data
Raphael Mannino
Chief Scientific Officer4.58yrsUS$294.64k0.73% $765.4k
Frank Calamusa
Executive Director and Head of Manufacturing & Supply Chain1.5yrsno datano data

1.5yrs

Average Tenure

52yo

Average Age

Experienced Management: MTNB's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jerome Jabbour
Co-Founder2.08yrsUS$1.33m0.41% $428.9k
Patrick LePore
Independent Vice Chairman of the Board1.58yrsUS$160.00k0.15% $161.0k
Herbert Conrad
Independent Chairman of the Board6.75yrsUS$176.00k2.25% $2.4m
Adam Stern
Director6.75yrsUS$130.00k1.15% $1.2m
James Scibetta
Independent Director6.42yrsUS$155.00k0.31% $331.3k
David Perlin
Member of Scientific Advisory Board4.75yrsno datano data
Christie Ballantyne
Member of Scientific Advisory Board1.33yrsno datano data
Eric Ende
Independent Director3yrsUS$151.50k0.057% $59.9k
J. Craft
Member of Scientific Advisory Boardno datano datano data
Kevin Maki
Member of Scientific Advisory Boardno datano datano data

3.9yrs

Average Tenure

54.5yo

Average Age

Experienced Board: MTNB's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MTNB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48%.


Top Shareholders

Company Information

Matinas BioPharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Matinas BioPharma Holdings, Inc.
  • Ticker: MTNB
  • Exchange: AMEX
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$105.453m
  • Shares outstanding: 196.56m
  • Website: https://www.matinasbiopharma.com

Number of Employees


Location

  • Matinas BioPharma Holdings, Inc.
  • 1545 Route 206 South
  • Suite 302
  • Bedminster
  • New Jersey
  • 7921
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTNBAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2014
6LJDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could encapsulate small molecules, gene therapies, vaccines, proteins, and peptides. The company’s lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. In addition, it provides MAT2501, an orally administered cochleate formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with ViiV Healthcare for the treatment and care for people living with human immunodeficiency virus. The company was founded in 2013 and is based in Bedminster, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 00:44
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.